Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Survey Highlights High Out-of-pocket Costs for RA Care

Richard Quinn  |  October 25, 2013

The out-of-pocket cost for rheumatoid arthritis (RA) treatment is between $1,000 and $5,000 per year, according to a recently released survey of more than 1,000 Americans.1

Figures from the survey, “RA in America 2013,” showed 44% of respondents spent between $1,000 and $5,000 per year, and nearly 15% of respondents spent more than $5,000 per year. Although the survey by Health Union, LLC, is not scientifically validated, it does raise “concerns,” says Jonathan Coblyn, MD, director of clinical rheumatology at the Center for Arthritis and Joint Diseases at Brigham and Women’s Hospital in Boston.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It didn’t surprise me, intellectually, but I was surprised to see almost half of RA patients are spending $5,000 a year out of pocket … and that is just for RA treatment,” says Dr. Coblyn, associate professor at Harvard Medical School and a member of ACR’s Communications and Marketing Committee. “They may be spending even more for other treatments. It’s unsettling because we have these drugs, which are terrific, and some patients will not have access to them.”

The survey, which presented data on topics ranging from impact on career and role of caregivers to flares and remission, also showed 44% of all RA patients have at one time or another avoided treatment due to cost.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This is a societal issue,” Dr. Coblyn adds. “That means approximately 30% of people with RA are going to avoid treatment due to expense, and we know that only 30% respond well to the low-cost therapies.”

Noting the high efficacy and “incredible expense” new biologic therapies offer, Dr. Coblyn says the survey results underscore physicians’ responsibility to control costs. He also emphasizes “deep dives” into patients’ ability to pay.

“If you fail at the low-priced triple therapy, and your patient continues to have active disease, to deny these drugs is pennywise and pound foolish,” he adds. “It has clearly been shown these drugs change the natural history of the disease. The balance, in the long run, is that they are probably still cost effective, despite the upfront cost.”


Richard Quinn is a freelance writer in New Jersey.

Reference

  1. Health Union. RA in America 2013. Available at http://rheumatoidarthritis.net/ra-in-america-2013/. Accessed October 9, 2013.

Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Out-of-pocket costsPatient costsRARheumatoid arthritisTreatment costs

Related Articles

    Rheumatologist Dr. Jonathan Coblyn Releases Stress by Fishing

    July 12, 2016

    Jonathan Coblyn, MD, was around 10 years old the first time his father took him fishing in April to Great South Bay, the largest shallow saltwater bay in New York. It was so cold that he remembers scraping frost off the lines that tied the family’s 26-foot motorboat to the pier. Dr. Coblyn, clinical chief…

    Tips for Handling Less Common Rheumatoid Arthritis-Related Disorders

    February 16, 2017

    WASHINGTON, D.C.—As treatments for rheumatoid arthritis (RA) improve, some related conditions that used to be common in patients with RA are not seen very often anymore, but they still exist and physicians need to know how to identify them. Speaking to attendees at the ACR/ARHP Annual Meeting talk titled Rheumatoid Arthritis—A Case-Based Approach to Selected…

    The Demise of the Inpatient Rheumatology Unit

    July 19, 2018

    Through much of the 20th century, dedicated rheumatic disease units were found in hospitals across the U.S. and countries around the world. In the latter part of the century, this began to change, with hospitals moving toward the consult model of care for rheumatic patients. This change reflects larger shifts in the medical world toward…

    Auto-Injectable Methotrexate: New Treatment Option for RA

    October 14, 2015

    Methotrexate has long been a cornerstone of therapy in rheumatoid arthritis. Two new, injectable methotrexate products may help some RA patients for whom oral methotrexate is not as effective or causes adverse effects. Rasuvo and Otrexup are prefilled, auto-injection devices that allow patients to give themselves subcutaneous injections of methotrexate without having to use a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences